Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks AXL-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced AXL activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas[1].
Tilvestamab (250 µM; 1 h) inhibits AXL phosphorylation in 786-0 cells[1].
Cell Viability Assay[1]
| Cell Line: | 786-0-Luc cells (Gas6- induced; Gas6 is a well characterized AXL ligand) |
| Concentration: | 250 µM |
| Incubation Time: | 1 h (pre-treat) |
| Result: | Drastically inhibited Gas6- induced AXL phosphorylation and decreased the level of pAKT. |
Tilvestamab (30 mg/kg; i.p.; twice a week) suppresses tumor growth by inhibiting AXL in orthotopic RCC model[1].
| Animal Model: | Female BALB/c athymic nude mice (8-week-old; orthotopic RCC model)[1]. |
| Dosage: | 30 mg/kg |
| Administration: | Intraperitoneal injection; twice a week |
| Result: | Significantly inhibited RCC growth down to about 1/3 of the volume. |
[1]. Chen TJ, et al. AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model. Physiol Rep. 2021 Dec;9(23):e15140.